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ProteolysisThe accumulation of β-amyloid (Aβ) peptide in the brain is one of the pathological hallmarks of Alzheimer's
disease and is thought to be of primary aetiological signiﬁcance. In an unbiased genetic screen, we identiﬁed
puromycin-sensitive aminopeptidase (PSA) as a potent suppressor of Aβ toxicity in a Drosophilamodel system.
We established that coexpression of Drosophila PSA (dPSA) in the ﬂies' brains improved their lifespan, protected
against locomotor deﬁcits, and reduced brain Aβ levels by clearing the Aβ plaque-like deposits. However, confo-
calmicroscopy and subcellular fractionation of amyloid-expressing 7PA2 cells demonstrated that PSA localizes to
the cytoplasm. Therefore, PSA and Aβ are unlikely to be in the same cellular compartment; moreover, when we
artiﬁcially placed them in the same compartment in ﬂies, we could not detect a direct epistatic interaction. The
consequent hypothesis that PSA's suppression of Aβ toxicity is indirect was supported by the ﬁnding that Aβ is
not a proteolytic substrate for PSA in vitro. Furthermore,we showed that the enzymatic activity of PSA is not required
for rescuingAβ toxicity inneuronal SH-SY5Y cells.We investigatedwhether the stimulation of autophagybyPSAwas
responsible for these protective effects. However PSA's promotion of autophagosome fusionwith lysosomes required
proteolytic activity and so its effect on autophagy is not identical to its protection against Aβ toxicity.
© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-SA license.1. Introduction
Many diseases in older people are characterized by the misfolding
and aggregation of a wide range of proteins [1–3]. Amongst the most
prevalent of these disorders is Alzheimer's disease (AD) in which the
β-amyloid (Aβ) peptide self-associates in a concentration-dependent
aggregation process [4] eventually forming amyloid plaques in the
brain [5,6]. Elevated Aβ levels are observed in the earliest stages of AD
[7] andmost, if not all, mutations that cause familial Alzheimer's disease
result in an increase in the production of aggregation-prone isoforms of
the peptide [8,9].
The resting concentration of Aβ results from a dynamic equilibrium
between its generation from the amyloid precursor protein (APP) andiversity of Cambridge, Downing
V.Open access under CC BY-NC-SA liceits clearance. While the production of Aβ has been studied extensively,
less is known about how the peptide is cleared from the brain. A number
of proteases have been characterized that directly cleave Aβ; the bulk of
the proteolytic capacity appears to be derived from three enzymes,
namely insulin-degrading enzyme (IDE) [10], endothelin-converting
enzyme (ECE) [11], and neprilysin (NEP) [12]. While the bulk of the Aβ
peptide is extracellular, these enzymes have been reported to be
localized to the cytosol and vesicular lumena (IDE) [10], bound to
membranes (ECE) [13] or extracellular (NEP) [14]. Overexpression or in-
hibition of these proteases in model systems has yielded the expected
consequences for Aβ levels and toxicity, for example, the overexpression
of neprilysinwas found to suppress the rough eye and reduced longevity
phenotypes in Aβ-expressing Drosophila [15]. Other clearance pathways
are important for misfolded cytoplasmic proteins, including autophagy
[16] and the ubiquitin–proteasome system [17]; both of these processes
also involve a protease termed puromycin-sensitive aminopeptidase
(PSA) [18,19]. Speciﬁcally, PSA has been shown to cooperate with the
proteasome to degrade polyQ-containing peptides in Huntington's
disease [18], appears to protect against tau toxicity in mouse and ﬂy
models of frontotemporal dementia (FTD) [20,21], and modulates
SOD1 levels in amyotrophic lateral sclerosis (ALS) [22]. In each of these
studies, the cleavage of the respective polypeptides by PSA has beennse.
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that tau is not directly degraded by PSA [25].
Our interest in PSA in the context of ADwas prompted by the results
of an unbiased genome-scale genetic modiﬁer screen in which we
searched for gene products thatwere able to rescue the reduced longev-
ity observed in ﬂies expressing Aβ. We identiﬁed PSA as one of the
most powerful suppressors of Aβ toxicity in our model system and in
this report, we investigate the protective mechanism.
2. Materials & methods
All reagents were purchased from Sigma-Aldrich unless otherwise
stated.
2.1. Fly stocks
Drosophila melanogaster expressing Arctic Aβ42 have been previous-
ly described [27]. NSP (no signal peptide) Arctic Aβ42 overexpressing
ﬂies were created by site-directed mutagenesis of Arctic Aβ42 in the
pUAST-AttB vector using the following primers: fwd 5′-AGGGAATT
GGGAATTCATGGATGCGGAATTTCGCC-3′ and rev 5′-GGCGAAATTCCGC
ATCCATGAATTCCCAATTCCCT-3′. UAS-Arctic Aβ42 and UAS-NSP Arctic
Aβ42 transgenic ﬂies were created by site-directed insertion using the
φC31 system at location 51D on the second chromosome [26]. Subse-
quently, the ﬂies were backcrossed for six generations into w1118 ﬂies
to obtain isogenic lines. A 51D line without insert but crossed to the
gal4 driver line was used as a negative control. UAS-dPSA RNAi
constructs, dPSA RNAi 1 (NIG stock ID: 1009 R-2) and dPSA RNAi 2
(NIG stock ID: 1009 R-3), were obtained from the National Institute of
Genetics Fly Stock Centre, Japan. TheUAS-dicer 2 constructwas obtained
from the Vienna Drosophila Research Center. UAS-dPSA lines were
created using pUAST transgenesis (PSA3-4, PSA3-7 and PSA8-10 were
unique inserts, each on the third chromosome).
2.2. Drosophila longevity assays
Flies were mated for 24 h after eclosion and females were entered
into longevity assays as described previously [27]. Unless otherwise
stated the ﬂies were cultured at 25 °C throughout the assay. Differences
in the survival phenotype were analyzed using Kaplan–Meier survival
plots and statistical signiﬁcance was determined using the logrank test.
2.3. Drosophila PSA RNAi expression
Flies carrying transgenes for the various Aβ42 variants were crossed
with the elavc155-gal4 driver line. The F1 offspringwere crossedwith the
dPSA RNAi lines and subsequently, the F2 offspring of the forgoing cross
with a UAS-dicer 2 line. One hundred mated female ﬂies, expressing
Aβ42 and Dicer 2, +/−PSA RNAi, were collected on the day of hatching.
Longevity assays were performed at 29 °C.
2.4. Locomotor assays
Negative geotaxis assays were performed as previously described
[28,29]. Fifteen ﬂies were assessed in three trials separated by 1 min.
2.5. Quantitation of Aβ peptides by ELISA
Drosophila were cultured at 25 °C for ﬁve days after eclosion and
then ﬁve heads were homogenized in 50 μl of 5 M guanidinium HCl,
5 mM EDTA, 50 mM HEPES, pH 7.3. Following centrifugation for
5 min at 13 krpm, 20 μl of the clear supernatant was removed and
mixed with 180 μl of 25 mM HEPES, pH 7.3, 1 mM EDTA, and 0.1%
(w/v) BSA with protease inhibitors (Complete, Roche). Triplicate 25 μl
aliquots were mixed with an equal volume of PBS containing 2% (w/v)
BSA, 0.2% (v/v) Tween-20, and protease inhibitors in the wells of aMESOmicrotiter plate (Meso Scale Discovery). The reactionwas started
by adding 25 μl of 4 μg/ml solutions of biotinylated 6E10 or 4G8mono-
clonal antibodies (Covance). After mixing, a further 25 μl aliquot of
1 μg/ml Ruthenium-labeled G2-10, or G2-11 (Millipore), monoclonal
antibody solution was added to each well. Following an overnight incu-
bation at room temperature (RT), the plates were washed twice with
PBS, 150 μl of MSD S Read Buffer (Meso Scale Discovery) was added,
and measured in a MSD Sector PR instrument (Meso Scale Discovery).
2.6. Fly brain lysates
Lysates of ﬂy heads were prepared as previously described [30].
2.7. Brain dissections, immunohistochemistry, and rough eye phenotyping
Brain dissections and immunohistochemistry were performed as
described previously [31].
2.8. Quantitative PCR
Messenger RNA was extracted from 100 ﬂy heads with the RNeasy
Mini kit (Qiagen) and quantiﬁed using theNanoDrop (Thermo Scientiﬁc).
Genomic DNA contamination was removed by treating 1 μg of RNA
sample with DNase. Subsequently, a reverse transcription reaction was
performed using an AMV Reverse Transcriptase kit (Promega). For quan-
titative PCR (qPCR), cDNA was diluted 1:100 in water and 10 μl was
pipetted into a 96-well plate with a SYBR-GREEN PCR master mix
(Bio-Rad). The quantitative PCR was performed using primers for Aβ
and dPSA (Aβ: fwd 5′-CAGCGGCTACGAAGTGCATC-3′ and rev 5′-
CGCCCACCATCAAGCCAATA-3′; dPSA: fwd 5′-AGAACTGCCTATGGGTGG
TG-3′ and rev 5′-TGTCATCGATCAATCCCAGA-3′). Differences in gene
expression levels between samples were normalized to expression levels
of the housekeeping gene RP49 (RP49: fwd 5′-ATGACCATCCGCCC
AGCATCAG-3′ and rev 5′-ATCTCGCCGAGTAAACG-3′). The reaction was
carried out in an iQ5 iCycler (Bio-Rad) thermocycler. The SYBR green
ﬂuorescence was used to compare mRNA levels. For each sample, the
ﬂuorescence was averaged between the replicates and normalized to
the respective RP49 ﬂuorescence level (ΔΔCT) as well as to potential
noise present in the non-template controls. At least ﬁve replicates of
each sample were carried out and the standard deviation calculated.
2.9. Human PSA constructs
Expression constructs for full-length human PSA (GFP-PSA) and the
enzymatically inactive mutant of PSA (GFP-ZBD) with N-terminal GFP
tags in the pEGFP-C3 vector were prepared. A non-ﬂuorescent (NF)
version for each GFP construct (pEGFP-C3, GFP-PSA, and GFP-ZBD)
was obtained by mutating two residues (T65S and Y66A) of the GFP
ﬂuorophore by site-directed mutagenesis. In addition, constructs
(GFP-PSA and GFP-ZBD in the pTRE2hyg vector) for making the induc-
ible HeLa Tet-On stable cell lines were generated. The GST-PSA/pET-41
Ek/LIC construct was generously provided by Dr. Stanislav Karsten
(UCLA, USA) [20,23]. The inactive GST-ZBD construct was obtained by
site-directed mutagenesis. The detailed cloning strategy may be found
in the supplementary data.
2.10. Cell culture and transfection
7PA2 cells, kindly provided by Prof. Dennis Selkoe (HarvardMedical
School, Cambridge, MA, USA), and the parental CHO (Chinese Hamster
Ovary) cells were grown as described previously [32]. SH-SY5Y cells
were grown in DMEM:nutrient mixture F-12 (DMEM/F-12) containing
10% (v/v) FBS. HeLa Tet-On cells (Clontech) were cultured in DMEM
containing 10% (v/v) Tet System Approved FBS (Australia-sourced,
Clontech) and G418 (200 μg/ml, Invitrogen). The set of constructs
(GFP-PSA, and GFP-ZBD in the pTRE2hyg vector) was transfected
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by hygromycin B (Invitrogen) resistance (500 μg/ml) according to
Clontech's instructions. The HeLa Tet-On stable cell lines (GFP-PSA
and GFP-ZBD) weremaintained in HeLa Tet-On cell medium containing
200 μg/ml hygromycin B. All cells were incubated at 37 °C and 5% (v/v)
CO2.
For transient transfections, 7PA2 cells were plated in medium
lacking antibiotics on poly-L-lysine coated surfaces and transfected
using Lipofectamine 2000 (Invitrogen) according to themanufacturer's
instructions.
2.11. Autophagy
Expression of GFP-PSA and GFP-ZBD in HeLa Tet-On stable cell lines
was induced by treatment with 1 μg/ml doxycycline for 48 h. To
knock down PSA, parental HeLa Tet-On cells were transfected with
200 pmol ON-TARGETplus SMARTpool siRNA against human PSA/
NPEPPS (Dharmacon) using Lipofectamine 2000 according to the
manufacturer's protocol, and lysed 48 h post-transfection. For the
mock transfection, the siRNA was replaced with Opti-MEM. Four
hours before harvesting, cells were either left untreated or treated
with 400 nM baﬁlomycin A1 [33]. Cell lysates were separated by SDS-
PAGE and the bands on the immunoblots were quantiﬁed by densitom-
etry using ImageJ.
2.12. Indirect immunoﬂuorescence and confocal microscopy
Twenty-four hours post-transfection, cells were washed with PBS
and ﬁxed with 4% (v/v) paraformaldehyde (Electron Microscopy
Sciences) in PBS for 20 min. After ﬁxation, cells were washed three
times with PBS, permeabilized with 0.2% (v/v) Triton X-100 for 5 min,
and blocked in 1% (w/v) BSA in PBS for 30 min. Subsequently, cells
were incubated with the following primary antibodies for 1 h at RT in
a humidiﬁed chamber: a 1:50 dilution of goat polyclonal PSAP (N-20)
(Santa Cruz Biotechnology) antibody against PSA and a 1:800 dilution
of mouse monoclonal antibody against GFP (Abcam). After washing
three timeswith PBS, cells were incubatedwith the appropriate second-
ary antibodies (Alexa Fluor 633 donkey-anti goat IgG and Alexa Fluor
546 donkey anti-mouse IgG, Invitrogen) for 45 min at RT in a humidi-
ﬁed chamber. After washing the cover slips four to ﬁve times with
PBS, they were mounted with ProLong Gold Antifade (Invitrogen).
Single slices or z-stacks were acquired with a Zeiss LSM 510 confocal
microscope (Carl Zeiss) using the 100× objective and were processed
with the Zeiss LSM Image Browser.
2.13. SDS-PAGE andWestern blotting of cell lysates and conditioned media
∅10 cm plates of 7PA2 cells were conditioned with 10 ml DMEM,
the conditioned medium (CM) collected after 18 h and cleared of cell
debris. After adding protease inhibitors (Complete, EDTA-free, Roche),
the CM was concentrated at least 20–30 times in Vivaspin 2 PES
columns (3000 MWCO, Sartorius Stedim Biotech) for Aβ or Vivaspin
20 PES columns (30,000 MWCO, Sartorius Stedim Biotech) for PSA at
4 °C according to the manufacturer's instructions.
Twenty-four hours post-transfection, cell lysates were prepared in
lysis buffer (10 mM Tris, pH 7.4, 10 mM NaCl, 1% (v/v) NP-40 with
protease inhibitors), boiled in SDS loading buffer, and separated by
SDS-PAGE on 8%, 10%, 12% or 15% PAA gels depending on the size of
the protein-of-interest. The protein bands were transferred on to
PVDF or nitrocellulose membranes (both 0.45 μm) and blocked with
5% (w/v) fat-free milk powder in PBS-T (0.05% (v/v) Tween-20 in PBS)
for 1 h at RT. The sensitivity of Aβ immunoblotting was increased by
boiling the nitrocellulose membrane in PBS for 10 min [34–36], before
blocking. The membranes were probed overnight at 4 °C with the fol-
lowing primary antibodies: goat polyclonal PSAP (N-20) against PSA
(1:200, Santa Cruz Biotechnology), rabbit polyclonal to GFP (1:1000,Abcam), mouse monoclonal AC-15 against β-actin (1:5000, Sigma),
mousemonoclonal against eIF2α (1:10,000, a gift fromDavid Ron, Insti-
tute for Metabolic Science, Cambridge, UK) [37], mouse monoclonal
10C3 against KDEL (1:1000, Stressgen), mouse monoclonal 6E10
against APP (Aβ 1–16) (1:1000, Covance), mouse monoclonal 4G8
against APP (Aβ 17–24) (1:1000, Covance), rabbit monoclonal 139-5
against β amyloid 40 (1:2000, Covance), rabbit polyclonal to histone
H3 (1:1000, Cell Signalling), or rabbit polyclonal against LC3 (1:2000,
Novus Biologicals). The membranes were washed three times with
PBS-T and then incubated with the corresponding HRP-conjugated
secondary antibody for 1 h at RT. After washing the membrane three
times with PBS-T and once with PBS, the protein bands were detected
with the SuperSignal West Pico and/or Femto Chemiluminescent
Substrate (Pierce Biotechnology) according to the manufacturer's
protocol and exposed to X-ray ﬁlm (Fujiﬁlm).
2.14. Subcellular fractionation by density gradient ultracentrifugation
Forty-eight hours post-transfection, three Ø10 cm plates of 7PA2
cells (untransfected or transiently expressing pEGFP-N3, GFP-PSA, and
PSA-GFP) were washed once with ice-cold PBS and then processed
using a ball-bearing homogenizer with a 10 μm clearance (EMBL,
Heidelberg, Germany) as previously described [38]. The homogenate
was cleared of cell debris by centrifugation at 3000 ×g for 10 min at
4 °C (an “input” aliquot was taken) and adjusted to 35% (v/v) OptiPrep.
Membranes were ﬂoated by centrifugation at 70,000 ×g for 2 h at 4 °C
to the interface of a discontinuous 0%–30% (v/v) OptiPrep gradient
buffered with 20 mM HEPES, pH 7.4 and 1 mM EDTA. An aliquot of
the so-called depleted cytosol in 35% (v/v) OptiPrep was taken. The
membranes were washed by diluting the membrane-enriched fraction
1:5 with homogenization buffer and repelleted by centrifugation at
100,000 ×g for 45 min at 4 °C. The pelletswere pooled by solubilization
in a total volume of 50 μl homogenization buffer.
2.15. Nuclear and cytoplasmic fractionation
One conﬂuent ∅10 cm plate of 7PA2 cells was washed twice with
ice-cold PBS, harvested in PBSwith 1 mMEDTA, and collected by centri-
fugation at 1000 ×g for 5 min at 4 °C. The cell pellet was resuspended in
200 μl harvest buffer [10 mM HEPES pH 7.9, 50 mM NaCl, 500 mM su-
crose, 0.1 mM EDTA, 0.5% (v/v) Triton X-100 supplemented with 1 mM
DTT, 1 mM PMSF, protease inhibitors (Complete, EDTA-free, Roche)]
and placed on ice for 5 min (an “input” aliquot was taken). After centri-
fugation at 100 ×g for 10 min at 4 °C, the supernatantwas taken off and
kept as the post-nuclear supernatant (PNS). The pellet corresponds to
the nuclei and was washed four to ﬁve times with 500 μl low-salt
wash buffer (10 mM HEPES, pH 7.9, 10 mM KCl, 0.1 mM EDTA,
0.1 mMEGTA) to eliminate any cytoplasmic contamination. The nuclear
pellet was recovered by centrifugation at 100 ×g for 5 min at 4 °C,
resuspended in 100 μl high-salt extraction buffer [10 mM HEPES
pH 7.9, 500 mM NaCl, 0.1 mM EDTA, 0.1 mM EGTA, 0.1% (v/v) NP-40],
and vortexed for 15 min at 4 °C. Centrifugation at 18,000 ×g for
10 min at 4 °C gives rise to the nuclear extract (NE) as the supernatant
containing all soluble nuclear proteins and the pellet consisting of the
remaining insoluble proteins, which was solubilized in 4× SDS loading
buffer. The input and nuclear insoluble fraction (NI) were sheared ﬁve
times with a 25 G hypodermic needle.
2.16. Aminopeptidase activity assay
Forty-eight hours post-transfection, one conﬂuent∅10 cm plate of
SH-SY5Y cells (untransfected or transiently expressing pEGFP-N3,
GFP-PSA, or GFP-ZBD) was washed once with PBS and harvested in
500 μl PBS containing 0.5 mM EDTA. After centrifugation for 10 min at
3000 ×g, the cell pellet was washed once with 500 μl PBS, resuspended
in 100 μl of 10 mM Tris, pH 7.4, and incubated on ice for 10 min. The
2118 A.J. Kruppa et al. / Biochimica et Biophysica Acta 1832 (2013) 2115–2126cells were homogenized by ultrasonication and centrifuged for 30 min
at 13,000 ×g at 4 °C. The supernatant containing the soluble fraction
was collected and the protein concentration was measured at A280 nm
using the NanoDrop (Thermo Scientiﬁc). The aminopeptidase activity
assay was performed as described (http://www.sigmaaldrich.com/
img/assets/18160/Aminopeptidase.pdf) with the following revisions:
the reaction cocktail used a 2 mM L-leucine-p-nitroanilide solution;
150 μg of lysate was added to the reaction; the lysates were inhibited
with 10 μM puromycin; the reaction was prepared in 1 ml and then
200 μl was immediately transferred to a 96-well plate in triplicate; the
assay was carried out at RT. The A405 nm was monitored at RT every
5 s for 1 h in a ThermoMax microplate reader (Molecular Devices).
Initial reaction rates (45 min) of substrate digestion were calculated
and plotted in GraphPad Prism 4.
2.17. Aβ toxicity assay
Twenty-four hours post-transfection, SH-SY5Y cells were replated in
triplicate into a 96-well plate. After the cells had reattached (~4 h), they
were washed once with Opti-MEM and treated with 100 μl of 10 μM
monomeric Aβ1–42 [39–41] in Opti-MEM for 48 h at 37 °C and 5%
(v/v) CO2. All wells were washed once with 100 μl D-PBS. One hundred
microliters of a 3 μM working solution of both dyes [calcein AM and
ethidium homodimer-1 from the LIVE/DEAD Viability/Cytotoxicity kit
(for mammalian cells), Invitrogen] in DMEM/F-12 medium (no phenol
red) was added to each well, incubated at RT for 45 min, and the ﬂuo-
rescence signal was read using the EnVision XCite Multilabel Reader
(Perkin Elmer). The numbers of live and dead cells were determined,
converted to a calcein AM/ethidium homodimer-1 (Live/Dead cell)
ratio, and displayed graphically in GraphPad Prism 4.
2.18. Puriﬁcation of recombinant GST-tagged PSA and inactive GST-ZBD
The GST-PSA and GST-ZBD constructs were transformed into
Rosetta2(DE3)pLysS bacterial cells and grown in LB medium at 37 °C
until OD 0.8 at A600 nm, before induction with 1 mM IPTG and overnight
expression at 18 °C in a fermenter. Cell pellets were resuspended in PBS
containing 0.1 mg/ml lysozyme and 10 μg/ml DNaseI and incubated at
4 °Cwith stirring for 30 min. The cell suspension was disrupted by son-
ication and cleared by centrifugation at 25,000 ×g for 30 min at 4 °C.
The clariﬁed supernatant was incubated with Glutathione Sepharose
4B beads (GE Healthcare) for 2 h at 4 °C on a rotating platform. After
washing the beads with PBS containing 0.5 M NaCl, the GST fusion pro-
teins were eluted from the resin with 20 mM reduced L-glutathione,
100 mM Tris, pH 8, and 50 mM NaCl. GST-tagged PSA and the inactive
GST-ZBD recombinant proteins were dialyzed into 20 mM Tris, pH 7.4
and 100 mM NaCl overnight using Slide-A-Lyzer Mini Dialysis Units
(10,000 MWCO, Thermo Scientiﬁc). The protein concentration was
determined with the NanoDrop using a calculated mass extinction
coefﬁcient of 14.45 l g−1 cm−1 for GST-PSA and 14.46 l g−1 cm−1 for
GST-ZBD [42]. The aminopeptidase activity of GST-PSA and inactivity
of GST-ZBD were determined using 2 μg enzyme in 10 mM Tris,
pH 7.4 containing 1 mM DTT (required for PSA activity). The reaction
was initiated with L-leucine-p-nitroanilide at a ﬁnal concentration of
500 μM andmonitored at A405 nm every 10 s for 5 min in a ThermoMax
microplate reader (Molecular Devices) at RT.
2.19. In vitro digestion assay
Monomeric Aβ1–40 was dissolved at 1 μg/μl in 20 mM Tris, pH 7.4,
100 mM NaCl. The in vitro digestion assay (50 μl total volume) was set
up as follows: 11.5 μM Aβ1–40 was pipetted into the reaction buffer
(20 mMTris, pH 7.4, 100 mMNaCl) containing 1 mMDTT and initiated
by adding 0.8 μMof GST-PSA (the preparation's activity had been deter-
mined as described above). The reaction tubes were incubated at 30 °C
for 0, 1/2, 2, 6, and 24 h and stopped at the designated time points bythe addition of 2× Tricine SDS Sample Buffer and snap-freezing on dry
ice. The Aβ band from the 24 h timepoint was analyzed by N-terminal
protein sequencing (Edman degradation). As negative controls,
GST-PSAwas incubatedwith Aβ1–40 in the presence of 100 μMpuromy-
cin (PSA inhibitor) for 24 h and the inactivemutant, GST-ZBD,was incu-
bated with Aβ1–40 for 24 h.
3. Results
3.1. An overexpression screen of the Drosophila autosome identiﬁed
puromycin-sensitive aminopeptidase as a suppressor of Aβ toxicity
Aβ toxicity was modeled in Drosophila melanogaster by fusing Aβ to
an N-terminal secretion signal peptide and expressing it in the central
nervous system of the ﬂy [27]. This approach does not require the
proteolytic processing of APP and permits the convenient study of
pathological processes that are downstream of Aβ generation. In order
to identify novel genetic modiﬁers of Aβ toxicity in the ﬂy, a library of
3000 unique genomic insertions of the gene search (GS)mobile genetic
element was generated and the effect of the consequent gal4-
dependent modulation of neighboring gene transcription on the
lifespan of ﬂies expressing the Arctic variant (E22G) of Aβ42 [43] was
assessed. Insertion 622 provided one of the most powerful suppressor
effects resulting in an increase in median survival from 29 days in ﬂies
expressing Arctic Aβ42 (n = 72) to 36 days in ﬂies expressing both
Aβ42 and the GS622 element (n = 27 ﬂies, p b 0.001 by logrank test).
Inverse PCR demonstrated that the insertion of the GS element was on
chromosome 3 in the 5′ untranslated regions of two genes. The ﬁrst
gene was the Drosophila ortholog of puromycin-sensitive aminopepti-
dase (dPSA, CG1009) and the second was cue, an ortholog of the low
density lipoprotein receptor (CG12086).
To gain an insight intowhich of these geneswasmore likely to be in-
volved in modulating Aβ toxicity in the ﬂy, an Affymetrix cDNA micro-
array screenwas undertaken to search for genes thatwere up- or down-
regulated in ﬂies expressing Arctic Aβ42 as compared to ﬂies expressing
the non-toxic Aβ40 peptide [44]. In this study, the mRNA for dPSA
exhibited a 2.7-fold upregulation in Arctic Aβ42 ﬂies (false detection
rate 1.5%), whereas the mRNA for CG12086 was not differentially regu-
lated. To further deﬁne whether dPSA or CG12086 was responsible for
the rescue of Aβ toxicity, ﬂies were generated that overexpressed
each gene individually. Three representative transgenic lines of ﬂies
for each gene were chosen and the effects of each transgene on
longevity in ﬂies coexpressing Arctic Aβ42 were measured. None of the
overexpression constructs for CG12086 were able to replicate the sup-
pression of Arctic Aβ42 toxicity; in contrast, all three independent trans-
genic ﬂy lines coexpressing dPSA with Arctic Aβ42 demonstrated an
increase in median survival (Fig. 1A, n = 100 ﬂies for all lines,
p b 0.001 by logrank test for all three UAS-dPSA lines with Arctic Aβ42
vs. Arctic Aβ42 alone). By contrast, dPSA expression in control ﬂies
caused a mild reduction in longevity (Supplementary Fig. 1). dPSA
suppressed the retinal toxicity associated with Arctic Aβ42 expression
resulting in normal eye development (Fig. 1B). The ﬂies were also func-
tionally protected as shown by improved locomotor function through-
out their adult life as compared to ﬂies expressing Arctic Aβ42 alone
(Fig. 1C). Confocal microscopy of ﬂy brains stained with the 6E10
antibody for Aβ42 revealed that Arctic Aβ42 ﬂies exhibit profuse
plaque-like deposits, whereas coexpression with dPSA resulted in a
marked reduction in the number of Aβ deposits (Fig. 1D). An ELISA
assay conﬁrmed that total Arctic Aβ42 levels were reduced in brains of
Arctic Aβ42 ﬂies coexpressing dPSA compared to Arctic Aβ42 alone
(Fig. 1E). This reduction in peptide accumulation is unlikely to be an
artefactual genetic interaction, as there was no correlation between
AβmRNA levels (asmeasured by qPCR) from ﬂy brains andmedian sur-
vival (data not shown). Essentially identical results were observed
when lifespan and locomotor assays were repeated with ﬂies
coexpressing dPSA with wild-type Aβ42 (data not shown).
Fig. 1. Coexpression of dPSAwith Arctic Aβ42 inDrosophilamelanogaster. (A) Transgenic overexpression of dPSA in Arctic Aβ42ﬂies (gray, three independent transgenic lines) prolonged their
lifespan compared toﬂies expressingArctic Aβ42 alone (white) andalmost completely rescued the longevity phenotype compared to controlﬂies (black). n = 100ﬂies,mean ± S.E., logrank
test. (B) Elavc155-gal4-driven expression of Arctic Aβ42 from two transgenes resulted in a rough eye phenotype that was suppressed by coexpression with dPSA (Arctic Aβ42 + dPSA).
(C) Locomotor assays were performed on three independent groups of ten to ﬁfteen ﬂies for each of the genotypes on days 1, 10, and 20 of adult life. For each age group, the locomotor
data for the three independent transgenic lines of dPSA were pooled. Throughout their lives ﬂies coexpressing dPSA with Arctic Aβ42 (gray, three replicates for each of the three transgenic
lines)weremarkedlymoremobile thanﬂies expressingonlyArctic Aβ42 (white, three replicates). In comparison to controlﬂies (black, three replicates), overexpression of dPSA alleviated the
majority of the locomotor impairment caused by Arctic Aβ42 at all time points. n = 3, mean ± S.E., one-tailed unpaired t-test. (D) Elavc155-gal4-driven expression of Arctic Aβ42 from two
transgenes resulted in profuse plaque-like deposits of Aβ thatwere clearedwhen dPSAwas co-expressed (Arctic Aβ42 + dPSA). Aβwas detectedwith the 6E10 antibody (red) andDNAwas
stainedwith TOTO-3 (blue). Imageswere collectedwith a confocalmicroscope. Quantitation of the confocal slices revealed that dPSA clears 75%of the plaques as compared to Arctic Aβ42ﬂies
alone. n = 4 ± S.D., two-tailed unpaired t-test. (E) Coexpression of dPSAwith Arctic Aβ42 (gray) reduced the concentration of Aβ42 in the heads of all three transgenic ﬂy lines compared to
ﬂies expressing Arctic Aβ42 alone (white) asmeasured byMSD ELISA. Representative of two repeats: n = 3 (three replicates), mean ± S.D., one-tailed unpaired t-test. *p b 0.05; **p b 0.01;
***p b 0.001.
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substrate for PSA due to uncertainty in the subcellular localization of
the protease [24,45–47].
3.2. Mammalian PSA is localized in the cytoplasm and is not membrane-
bound in 7PA2 cells
To precisely establish its intracellular distribution, human PSA was
taggedwith GFP at the N-terminus (GFP-PSA) and transiently transfected
into CHO cells overexpressing human APP751 with the V717F familial AD
linked mutation. These cells termed 7PA2 predominantly secrete Aβ42
[32]. GFP-PSA was localized to the cytoplasm of 7PA2 cells, colocalizing
with antibodies against GFP and PSA by indirect immunoﬂuorescence
(Fig. 2A). As expected, the GFP control was distributed uniformly within
both the cytoplasm and nuclei of cells transiently transfected with thecontrol vector (pEGFP-C3) (Fig. 2A). Western blotting of the correspond-
ing lysates with PSA and GFP antibodies conﬁrmed that the full-length
GFP-PSA fusion protein was expressed at the correct size (130 kDa) as
was GFP from the control vector (pEGFP-C3) at ~30 kDa (Fig. 2B). In ad-
dition, the PSA antibodywas able to detect endogenous PSA at 100 kDa in
the 7PA2 cell lysates (Fig. 2B).
Subcellular fractionation of 7PA2 cells by density gradient ultracen-
trifugation revealed that endogenous PSA and overexpressed GFP-PSA
were mainly present in the depleted cytosol fraction and not associated
with membranes (Fig. 2C). Transiently transfecting the control vector
(pEGFP) expressing GFP into 7PA2 cells had no effect on the localization
of endogenous PSA (Fig. 2C). When nuclei were isolated from 7PA2
cells, endogenous PSA was mainly located in the post-nuclear superna-
tant (conﬁrming its cytoplasmic location) and was not present in the
nuclear extract or nuclear insoluble fraction (Fig. 2D).
Fig. 2. Intracellular localization of endogenous andGFP-taggedPSA in 7PA2 cells. (A) Indirect immunoﬂuorescence of 7PA2 cells transiently transfectedwith the control vector (pEGFP-C3)
and a construct expressing PSA tagged with GFP (green) at the N-terminus (GFP-PSA). The GFP-PSA fusion protein colocalized with antibodies against GFP (red) and PSA (blue) in the
cytoplasm. Images were collected with a confocal microscope and the merged panel is shown on the far right. (B) Lysates of untransfected cells (CHO and 7PA2), 7PA2 cells transiently
transfected with pEGFP-C3 and GFP-PSA were prepared and separated by SDS-PAGE. The Western blot was probed with antibodies against PSA and GFP. The GFP-PSA fusion protein
was expressed at the correct size of 130 kDa and endogenous PSA could be detected at 100 kDa. β-actin is shown as a loading control. (C and D) Subcellular fractionation of 7PA2 cells
by density gradient ultracentrifugation. Membranes were prepared from untransfected 7PA2 cells and cells transiently transfected with pEGFP-N3 and GFP-PSA. Nuclei were isolated
from 7PA2 cells. Samples were separated by SDS-PAGE and the immunoblot was probed with a PSA antibody. Endogenous PSA and overexpressed GFP-PSA were cytosolic and could
not be detected in the membrane or nuclear fractions. The following loading controls were used: eIF2α (cytoplasmic), KDEL (membranes), APP (detected by the 6E10 antibody), and
histone H3 (nuclear). PNS: post-nuclear supernatant, NE: nuclear extract, NI: nuclear insoluble. (E) 7PA2 cell lysates were prepared and the corresponding conditioned medium (CM)
was collected and concentrated. The samples were separated by SDS-PAGE and the immunoblot was probed with PSA and 6E10 (detects the ﬁrst sixteen amino acids of Aβ) antibodies.
PSA could not be detected in the extracellular medium. β-actin is shown as a loading control.
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interacting with Aβ in the extracellular space. However, PSA could
not be detected in concentrated conditioned medium of 7PA2 cells
(Fig. 2E).
3.3. Drosophila PSA does not interact with Arctic Aβ42 in the cytoplasm of
ﬂy neurons
One possible explanation for how cytoplasmic PSA can rescue
phenotypes mediated by supposedly extracellular Aβ is that a highly
toxic subpopulation of Aβ migrates into the cytoplasm where it exerts
its deleterious effects. To test whether PSA can protect against a cyto-
plasmic Aβ challenge, we generated transgenic ﬂies expressing Arctic
Aβ42 without a secretion signal (NSP: no signal peptide; NSP Arctic
Aβ42). Expression of secreted Arctic Aβ42 in the brain of ﬂies resulted
in the accumulation of peptides that appear as monomers following
SDS-PAGE (Fig. 3A, Arctic Aβ42 lane), while NSP Arctic Aβ42 appeared
as an oligomeric species (NSP Arctic Aβ42 lane). Despite similar expres-
sion levels as determined by qPCR (Fig. 3B), the lifespan of NSP Arctic
Aβ42 ﬂies did not differ from control ﬂies indicating that cytoplasmic
Aβ is not toxic (Fig. 3C). If dPSA is indeed responsible for protection
against a toxic cytoplasmic fraction of Aβ, then dPSA knockdown shouldinteract more strongly with NSP Aβ as compared to secreted Aβ. To de-
tect whether a reduction in dPSA levels might enhance the toxicity of
NSP Arctic Aβ42, we used two independent dPSA-RNAi lines (1 and 2)
coexpressed with Dicer-2 (Fig. 3D). In control ﬂies (Fig. 3E, Control),
the knockdown of dPSA using both RNAi lines (Fig. 3E, Control + dPSA
RNAi 1 & Control + dPSA RNAi 2) caused a reduction in longevity due
to background genetic effects unrelated to Aβ toxicity. In ﬂies express-
ing NSP Arctic Aβ42, the pattern of longevity reduction was remarkably
similar to control ﬂies, which is consistent with cytoplasmic Aβ not
interacting with dPSA. In contrast, the pattern of longevity changes
was quite distinct following dPSA knockdown in ﬂies expressing secret-
ed Arctic Aβ42, thereby supporting an interaction between secreted Aβ
and dPSA (Fig. 3E). Although the nature of the interaction remains
unclear, the particular conformation of Aβ in the neuronal environment
may be important or else the ﬂies may die of Arctic Aβ42 toxicity before
the effect of dPSA RNAi can be observed. Similarly, an interaction
between cytoplasmic Aβ and PSA could not be observed at the tissue
level. In ﬂies expressing NSP Arctic Aβ42, the appearance of plaque-like
deposits could not be induced (Fig. 3F), even when endogenous PSA
was knocked down using RNAi (NSP Arctic Aβ42 + Dicer-2 + dPSA
RNAi). Our positive controls were ﬂies expressing secreted Arctic Aβ42,
which spontaneously formed plaque-like deposits (Fig. 3F).
Fig. 3. dPSA does not participate in the clearance of cytoplasmic Arctic Aβ42 in vivo. (A)Western blot analysis of the PBS-soluble fraction of control and transgenic ﬂy brain extracts probed
with the 6E10 antibody against Aβ. Thematerial fromArctic Aβ42 ﬂies ismonomeric, whereas NSP (no signal peptide) Arctic Aβ42 ﬂies form soluble oligomeric species.β-actin is shown as
a loading control. (B) Quantitative real-time PCR (qPCR) demonstrating that the mRNA levels of Arctic Aβ42 (white) and NSP Arctic Aβ42 (gray) are similar. Gene expression values were
normalized to the mRNA level of the housekeeping gene RP49. n = 5 (ﬁve replicates), mean ± S.D. (C) Transgenic overexpression of NSP Arctic Aβ42 (gray squares) in the cytoplasm of
ﬂies is non-toxic as their lifespan is similar to control ﬂies (black circles). In comparison, expression of Arctic Aβ42 (white triangles) in the secretory pathway signiﬁcantly reduces their
longevity. n = 100 ﬂies (separated into groups of ten), mean ± S.D. (D) qPCR of dPSA levels in two RNAi lines (dPSA RNAi 1 and dPSA RNAi 2) with (white) and without Dicer-2
(gray). The knockdown efﬁciency of dPSA in both RNAi lines is improved in the presence of Dicer-2. Gene expression values were normalized to the mRNA level of the housekeeping
gene RP49. n = 6 (six replicates), mean ± S.D. (E) Control ﬂies not expressing Aβ (Control) and ﬂies expressing cytoplasmic NSP Arctic Aβ42 responded similarly to dPSA RNAi in the
presence of Dicer-2. By contrast, PSA knockdown inﬂies expressing secreted Arctic Aβ42 gave a distinct pattern of longevity effects. n = 100 ﬂies, mean ± S.D. (F) Dissections ofﬂy brains
illustrating plaque accumulation in Arctic Aβ42 ﬂies, which appears to be absent in NSP Arctic Aβ42 with or without dPSA (+Dicer-2 + dPSA RNAi). Aβ was detected with the 6E10
antibody (red) and DNA was stained with TOTO-3 (blue). Images were collected with a confocal microscope.
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toxicity
The aminopeptidase activity of neuronal SH-SY5Y cell lysates was
determined bymonitoring the hydrolysis of the chromogenic substrate,
L-leucine-p-nitroanilide. To estimate the contribution that endogenous
and overexpressed PSA made to the enzymatic activity, each lysate
was assayed in the presence (+P) and absence of puromycin
(Fig. 4A). SH-SY5Y cells transfected with the pEGFP-C3 control vector
or left untransfected had similar puromycin-sensitive activity, whereasthe expression of GFP-PSA markedly increased this activity (Fig. 4A). In
contrast, the single point mutation E309A [48] in the zinc-binding do-
main (ZBD) of PSA rendered the enzyme (GFP-ZBD, characterized in
Supplementary Fig. 2A and B) catalytically inactive (Fig. 4A). Equal
amounts of total protein were loaded in each reaction as demonstrated
by immunoblotting (Supplementary Fig. 2C).
Subsequently, the effect of overexpressing active GFP-PSA and inac-
tive GFP-ZBD in SH-SY5Y cells on the toxicity of exogenously applied
Aβ42 was assessed. To make our constructs spectrometrically compati-
ble with the LIVE/DEAD Cytotoxicity/Viability Kit, non-ﬂuorescent
Fig. 4. The rescue of Aβ42 toxicity in SH-SY5Y cells is independent of the proteolytic activity of PSA. (A) Aminopeptidase activity assay of GFP-tagged PSA expressed in SH-SY5Y cells. SH-
SY5Y cells (light gray)were transiently transfectedwith pEGFP-C3 (black), GFP-PSA (white), and the enzymatically inactive zinc-binding domain (ZBD)mutant (GFP-ZBD, dark gray). The
proteolytic activity of PSA in each lysate was inhibited by 10 μMpuromycin (P). Initial reaction rates of substrate digestionwere plotted. n = 3,mean ± S.E., ***p b 0.001, repeatedmea-
sures ANOVA followed by a Bonferroni'smultiple comparison post-hoc test. (B) Rescue of Aβ42 toxicity in SH-SY5Y cells by overexpression of GFP-tagged PSA and the inactivemutant. SH-
SY5Y cells were transiently transfectedwith non-ﬂuorescent GFP constructs (pEGFP-C3, GFP-PSA, and GFP-ZBD) and treatedwith 10 μMmonomeric Aβ42 in Opti-MEMmedium for 48 h.
The numbers of live and dead cells were measured using the LIVE/DEAD Viability/Cytotoxicity Kit; n = 3 (except for GFP-ZBDwhere n = 6), mean ± S.E.; ns, not signiﬁcant; *p b 0.05,
two-tailed paired t-test. (C) GST-tagged PSA does not digest Aβ40 in vitro. Recombinant GST-PSA or GST-ZBD were incubated either alone or in the presence of monomeric Aβ40 with or
without 100 μM puromycin (P) at pH 7.4 and 30 °C for up to 24 h. The samples were separated by SDS-PAGE and stained with Coomassie or the immunoblots were probed with an
antibody against PSA and a selection of Aβ antibodies: 6E10 (detects 1–16 of Aβ), 4G8 (detects 17–24 of Aβ), and Aβ40-speciﬁc 139-5 (C-terminal region of Aβ40).
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mutations (T65S Y66A) in the GFP ﬂuorophore (characterized in Sup-
plementary Fig. 3A, B and C). SH-SY5Y cells expressing enzymatically
active GFP-PSA NF were resistant to Aβ42 toxicity. In contrast, cells
transfected with the control pEGFP-C3 NF vector remained sensitive to
the toxic effects of Aβ42 (Fig. 4B). Surprisingly, and despite many
repeats, the rescue was also observed in cells expressing the inactive
mutant GFP-ZBD NF (n = 6, Fig. 4B and Supplementary Fig. 3D).
These data are compatible with a protective role for PSA against Aβ
toxicity, yet the proteolytic activity of PSA appears to be dispensable. In-
deed, we found that monomeric Aβ1–40 is not cleaved by recombinant
humanGST-tagged PSA in vitro over a 24 h time period (Fig. 4C). Specif-
ically, we could detect proteolysis neither on a Coomassie stained
SDS-PAGE gel nor by probing immunoblots with monoclonal anti-Aβ
antibodies chosen to monitor trimming activity. The Aβ peptide
remained intact under these conditions despite incubation with recom-
binant GST-PSA that retained N83% of its initial aminopeptidase activity
throughout the 24 h reaction.Moreover, N-terminal protein sequencing
of the Aβ band after the 24 h-incubation with GST-PSA identiﬁed a
single sequence (DAEFRHDS) corresponding to the ﬁrst eight amino
acids of the Aβ peptide with no detectable secondary species.
3.5. PSA regulates ﬂux through the autophagy pathway
Previous work has shown that PSA is particularly important for the
degradation of peptides containing polyglutamine stretches, which are
otherwise resistant to proteolysis by the proteasome [18]. Menzies
and colleagues have found in similar cell model systems that PSA can
further accelerate the clearance of such peptides by stimulatingautophagosome production [19]. To investigate the role of PSA in
regulating autophagy, we generated HeLa Tet-On stable cell lines
(see Supplementary Fig. 4) and measured LC3 II, a key marker of
autophagosomes.
Controlled overexpression of GFP-PSA resulted in a reduction in the
number of autophagosomes as shown by the decrease in basal LC3 II
levels (Fig. 5A). In contrast, siRNA-mediated knockdown of PSA in pa-
rental HeLa Tet-On cells led to an accumulation of autophagosomes,
which is evident from the increased LC3 II levels, under steady-state
conditions compared to mock-transfected cells (Fig. 5B). When we
pooled the data from the PSA-overexpression and PSA-RNAi experi-
ments and quantiﬁed total PSA (GFP-PSA and endogenous PSA) versus
LC3 II levels, we found a robust inverse correlation between the two
(Fig. 5C, black solid line, R2 = 0.92). The absence of a similar correlation
when we expressed inactive GFP-ZBD (Fig. 5C, gray dashed line) indi-
cated that PSA activity is required to modulate the autophagy pathway
and so reduce LC3 II levels.
Since LC3 II levels report the number of autophagosomes which in
turn depends on the dynamic equilibriumbetween autophagosome syn-
thesis and degradation, these data are insufﬁcient to determine whether
PSA is acting to slow autophagosome formation or alternatively to speed
their onward progression and fusion with lysosomes. To address this
uncertainty, we dissected the pathway using baﬁlomycin A1 (BFA)
which blocks autophagosome–lysosome fusion [49]. Upon BFA treat-
ment, we observed an invariant increase in LC3 II levels; remarkably
the elevated levels of LC3 II did not change regardless of whether GFP-
PSA or GFP-ZBD was overexpressed, or endogenous PSA was knocked
down by siRNA (Fig. 5D, E, F & Supplementary Fig. 5). The absence of a
correlation betweenPSA and LC3 II levels in the presenceof BFA indicates
Fig. 5.PSA levels regulate autophagicﬂux. (A andD)HeLa Tet-On stable cell lineswere treatedwith (+) orwithout (–) 1 μg/ml doxycycline (Dox) for 48 h to induce expression of GFP-PSA
and GFP-ZBD. (B and E) Endogenous PSAwas knocked down (PSA KD) in parental HeLa Tet-On cells (amock transfection is shown as a control) by siRNA and lysed 48 h post-transfection.
The samples were separated by SDS-PAGE and the immunoblot was probed with antibodies against PSA and LC3. β-actin is shown as a loading control. (D and E) The cells were treated
with 400 nM baﬁlomycin A1 (BFA) for 4 h before lysis. (C and F) Band intensities for total PSA comprised of endogenous PSA and GFP-PSA (black) or GFP-ZBD (gray), LC3 II, and β-actin
were quantiﬁed by densitometry using ImageJ and normalized to the respective control:−Dox (A and D) orMock (B and E). The results were displayed graphically by plotting PSA levels
against the corresponding LC3 II levels both relative to β-actin. R2 = 0.92 for the black PSA correlation in (C).
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(in the absence of BFA) relieves a block in autophagosome fusion with
lysosomes.
Taken together, these data indicate that enzymatically active PSA
can relieve a block in the fusion of autophagosomes with lysosomes.
This requirement for PSA to be active to permit autophagy stimulation
contrasts with PSA-mediated Aβ-protection where the active and inac-
tive isoforms of PSA are equally effective.
4. Discussion
Our screen for genetic modiﬁers of Aβ toxicity in the fruit ﬂy brain
identiﬁed a transposon-like P-element insertion that markedly
prolonged longevity. This enhancing genetic element was inserted be-
tween the gene for Drosophila PSA (dPSA, CG1009) and the ﬂy ortholog
of the lowdensity lipoprotein receptor (CG12086). As aﬁrst approach to
understanding which of the two genes was responsible for the rescue,
we consulted the results of our previous transcriptomic analysis of
ﬂies expressing Aβ versus controls. In this way, we found that PSA –
and not CG12086 –was upregulated in ﬂies expressing Aβ as compared
to control ﬂies. Interestingly, similar transcriptional upregulation of PSA
has also been reported in PC12 cells expressing huntingtin containing a
polyQ expansion, but not for normal huntingtin [50]. Moreover, PSA is
also induced in a mouse model expressing an FTD-linked variant of
tau [20]. In our study, further beneﬁts of PSA were investigated by gen-
erating transgenic ﬂies that coexpress either dPSA or CG12086 with Aβ.
We found that all three independent transgenic dPSA lines rescued Aβ
toxicity as evidenced by their ability to restoremedian survival towards
normal (Fig. 1A), suppress retinal toxicity (Fig. 1B), and slow the rate of
locomotor deterioration (Fig. 1C). By contrast, none of the CG12086-
overexpressing lines had beneﬁcial effects. Drosophila PSA also led to
clearance of Aβ plaque-like deposits (Fig. 1D) and reduced total Aβlevels in the brain (Fig. 1E) — an effect that could not be explained by
any confounding reduction in AβmRNA levels as determined by qPCR.
While it is attractive to assume that clearance of Aβ from these ﬂy
brains is a result of the proteolytic activity of PSA, certain prerequisites
must be fulﬁlled for this to be possible. The most important criterion
is that PSA and Aβ are present in the same compartment, whether
that be intra- or extra-cellular. It is generally believed that Aβ is gener-
ated in the lumina of vesicles or on the extracellular side of the plasma
membrane. In our model system, the Aβ peptide is secreted under the
control of a signal peptide, which is cleaved off in the process [51].
The subcellular localization of PSA has not been conclusively demon-
strated, although there are reports claiming it is secreted [52] these
have been widely discounted in favor of an intracellular distribution
(cytoplasmic [45], Golgi apparatus [53], and (peri)nuclear [54]) with a
possibility of being membrane-bound [47,55,56]. A crucial goal of this
study was to precisely locate PSA in our cell cultures and to determine
whether a signiﬁcant amount might cross membrane to come into con-
tact with extracellular Aβ (or vice versa). Both confocal microscopy of
cells expressing GFP-PSA (Fig. 2A) and density gradient ultracentrifuga-
tion clearly show that PSA is cytoplasmic and neither secreted (Fig. 2E),
nor associated with membranes (Fig. 2C), nor in the nucleus (Fig. 2D).
The ability of PSA to modulate Aβ toxicity, despite not being in the
same extracellular compartment, suggested another mechanistic possi-
bility: that a toxic fraction of the Aβ peptide may be acting in the cyto-
plasm. While this requires the Aβ peptide to cross the plasma
membrane, the same type of behavior has been described for a number
of aggregation-prone proteins [57,58]. To test whether cytoplasmic Aβ
could be toxic, we created ﬂies that expressed Aβ without a secretion
signal peptide. Surprisingly, these NSPﬂies exhibited no signs of toxicity
(Fig. 3C). mRNA expression levels of the cytoplasmic Aβ peptide
were essentially identical to its secreted counterpart (Fig. 3B), yet
we observed only minimal accumulation of the peptide in ﬂy brains
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rapid Aβ clearance from neurons, we set out to determine whether
RNAi-mediated knockdown of endogenous PSA could enhance the
toxicity of non-secreted Aβ. However, we found that control ﬂies and
ﬂies expressing cytoplasmic Aβ responded similarly to PSA RNAi indi-
cating that there is no epistatic interaction between PSA knockdown
and cytoplasmic Aβ when considering a measure of overall toxicity
such as ﬂy longevity (Fig. 3E). By contrast, there was a distinct pattern
of longevity changes in response to PSA RNAi in the ﬂies expressing
secreted Aβ (Fig. 3E) indicating again an epistatic interaction between
secreted Aβ and PSA knockdown.
Taken together, these data indicate that PSA and Aβ are unlikely to
be in the same subcellular compartment (Fig. 2) and, when artiﬁcially
placed in the same compartment, we cannot see a direct epistatic inter-
action (Fig. 3). Thus, it seems likely that PSA is not directly digesting Aβ,
but instead may involve a more indirect mechanism of action. This hy-
pothesis was supported by the in vitro ﬁnding that Aβ is not a proteolyt-
ic substrate for PSA (Fig. 4C). Furthermore, we demonstrated that the
protective role of PSA against Aβ toxicity is independent of its enzymatic
activity in SH-SY5Y cells (Fig. 4B). Theﬁnding that PSAhas a cellular role
that is distinct from its proteolytic activity is concordant with studies
into its orthologues in the plant kingdom. In particular, the orthologous
aminopeptidase M1 (APM1) in Arabidopsis thaliana possesses distinct
proteolytic and protein–protein interaction domains, both of which
are essential for normal development. Complementation analysis indi-
cates that these two activities do not need to be present in the same
polypeptide; indeed the plant enzyme can be complemented by expres-
sion, in trans, of orthologous domains of the human enzyme insulin-
responsive aminopeptidase [59]. Concordant with a proposed non-
proteolytic function for PSA, there is evidence from tauopathy model
systems indicating that proteolytic degradation is not the mechanism
by which PSA reduces protein deposition and rescues toxicity. In this
respect, several groups have shown that PSA reduces tau levels in
SH-SY5Y cells [24] and rescues a ﬂy model of tau toxicity [20], yet PSA
cannot cleave tau in vitro [25].
After discounting direct proteolysis, a strong candidate for PSA's
protective mechanism of action was the ability to stimulate autophagy.
Previous work has shown that, in cells expressing proteins with polyQ
expansions (as well as other aggregation-prone proteins), PSA is able
to cooperate with the proteasome to clear polyQ peptides [18], stimu-
lates autophagosome formation, and reduces inclusion body formation
[19]. For these reasons, we examined whether controlled expression
of our PSA constructs in stable HeLa Tet-On cell lines could accelerate
the formation of autophagosomes as evidenced by an increase in LC3
II levels. Under steady-state conditions, overexpression of GFP-PSA led
to a decrease in this autophagy marker, signaling a reduction in the
number of autophagosomes; the converse was true when PSA was
knocked down. When the data were pooled we could observe a clear
inverse linear correlation between the levels of enzymically active PSA
and the number of autophagosomes (Fig. 5C). However, when the
onward passage of autophagosomes was blocked by baﬁlomycin A1,
LC3 II levels became insensitive to PSA levels under all circumstances
(Fig. 5F). These observations indicate that PSA has proteolysis-
dependent activity that promotes autophagosome–lysosome fusion;
we have also seen that this activity can nonetheless be overwhelmed
by BFA blockade.
In summary, we show that the rescue from Aβ toxicity is not the
result of PSA proteolysis for two main reasons. Firstly, the two players
are unlikely tomeet in the same subcellular compartment and secondly,
PSA cannot cleave Aβ in vitro. As is the case for tau, the protection of PSA
from Aβ toxicity must be indirect. The regulation is unlikely to be tran-
scriptional as the Aβ expression in our ﬂy model is driven by a strong
neuronal driver andmRNA levels are not affected by PSA. In cell culture,
we could replicate the protective effects of PSA expression against
Aβ toxicity but found to our surprise that the inactive ZBD variant
of PSA was also beneﬁcial. We hypothesized that PSA may protectAβ-expressing ﬂies and cells by upregulating autophagy as has been
seen in models of Huntington's disease [19]. Pooling data from
overexpression and knockdown experiments in SH-SY5Y cells revealed
that PSA canmodulate autophagic ﬂux, however this effect requires the
enzyme to be active. We conclude that PSA is a strong suppressor of Aβ
toxicity, mediating its rescue by clearance of the peptide, but achieving
this without direct proteolysis. The requirement for PSA to be active in
order for it to stimulate autophagy makes this an unlikely explanation
for the protection that PSA affords versusAβ toxicity. The demonstration
of important roles for the protein–protein interaction domains in plant
orthologues of PSA indicates that a more indirect mechanism may be
important. That similar aminopeptidases may be activated by dimeriza-
tion provides a possible means by which our catalytically inactive PSA
could stimulate other potentially protective proteases [59]. However,
further work is required to understand the indirect mechanism(s) by
which PSA has beneﬁcial effects in multiple models of Alzheimer's dis-
ease and other neurodegenerative diseases.
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